Accéder au contenu
Merck

Synthesis of benzimidazole derivatives as potent β-glucuronidase inhibitors.

Bioorganic chemistry (2015-06-16)
Muhammad Taha, Nor Hadiani Ismail, Syahrul Imran, Manikandan Selvaraj, Hesham Rashwan, Fatin Ummi Farhanah, Fazal Rahim, Krishnan Selvarajan Kesavanarayanan, Muhammad Ali
RÉSUMÉ

Twenty five 4, 6-dichlorobenzimidazole derivatives (1-25) have been synthesized and evaluated against β-glucuronidase inhibitory activity. The compounds which actively inhibit β-glucuronidase activity have IC50 values ranging between 4.48 and 46.12 μM and showing better than standard d-saccharic acid 1,4 lactone (IC50=48.4 ± 1.25 μM). Molecular docking provided potential clues to identify interactions between the active molecules and the enzyme which further led us to identify plausible binding mode of all the benzimidazole derivatives. This study confirmed that presence of hydrophilic moieties is crucial to inhibit the human β-glucuronidase.

MATÉRIAUX
Numéro du produit
Marque
Description du produit

Sigma-Aldrich
Carbonate de sodium, anhydrous, powder, 99.999% trace metals basis
Sigma-Aldrich
Carbonate de sodium, BioXtra, ≥99.0%
Sigma-Aldrich
Benzimidazole, 98%
Sigma-Aldrich
β-glucuronidase from bovine liver, Type B-1, ≥1,000,000 units/g solid
Sigma-Aldrich
Carbonate de sodium, BioUltra, anhydrous, ≥99.5% (calc. on dry substance, T)
Sigma-Aldrich
8-Mercaptooctanoic acid, 95%
Sigma-Aldrich
Sodium carbonate-12C, 99.9 atom % 12C